Latest News for: maat

Edit

Availability of MaaT Pharma’s 2024 Universal Registration Document (URD) (Maat Pharma SA)

Public Technologies 14 Apr 2025
MaaT Pharma (EURONEXT ... About MaaT Pharma. MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival ... MAAT) since 2021.
Edit

MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 ...

Business Wire 08 Apr 2025
LYON, France--(BUSINESS WIRE)---- $MAAT #Cancer--MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT ... .
Edit

April 8, 2025: MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT (Maat Pharma SA)

Public Technologies 08 Apr 2025
) MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT ... Lyon, France, April 8th, 2025 - 7.30am CET - MaaT Pharma (EURONEXT ... About MaaT Pharma ... MAAT) since 2021.
Edit

MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT (Maat Pharma SA)

Public Technologies 08 Apr 2025
MaaT Pharma (EURONEXT ... The confirmed absence of a pre-specified mortality excess in patients receiving MaaT033 is of critical relevance", said Gianfranco Pittari, MD, PhD, Chief Medical Officer of MaaT Pharma ... About MaaT Pharma ... MAAT) since 2021.
Edit

Inside Information / Other news releases (Maat Pharma SA)

Public Technologies 08 Apr 2025
Lyon, France, April 8, 2025 - 7.30am CET - MaaT Pharma(EURONEXT ... About MaaT Pharma ... As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology ... MaaT Pharma has been listed on Euronext Paris (ticker.
Edit

MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co (Maat Pharma SA)

Public Technologies 07 Apr 2025
MaaT Pharma (EURONEXT ... Wainwright & Co initiated coverage of MaaT Pharma on April 4th, 2025 with a Buy recommendation and a Target Price of €21 ... About MaaT Pharma ... MaaT Pharma has been listed on Euronext Paris (ticker. MAAT) since 2021.
Edit

MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co

Business Wire 07 Apr 2025
LYON, France--(BUSINESS WIRE)---- $MAAT #Analysts--HC Wainwright & Co initiated coverage of MaaT Pharma with a Buy recommendation and a Target Price of €21 ... .
Edit

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the ...

Business Wire 05 Apr 2025
MaaT Pharma (EURONEXT. MAAT – the “Company”), a clinical-stage biotechnology company and a leader in ...
Edit

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital (Maat Pharma SA)

Public Technologies 04 Apr 2025
MaaT Pharma (EURONEXT ... About MaaT Pharma. MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival ... MAAT) since 2021.
Edit

MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve ...

Business Wire 01 Apr 2025
LYON, France--(BUSINESS WIRE)---- $MAAT #Cancer--MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies ... .
Edit

March 31, 2025: MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies (Maat Pharma SA)

Public Technologies 31 Mar 2025
) MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients' Responses to Immunotherapies. Lyon, France, March 31, 2025 - 6.00pm CET - MaaT Pharma (EURONEXT ... About MaaT Pharma ... MAAT) since 2021.
Edit

MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies (Maat Pharma SA)

Public Technologies 31 Mar 2025
MaaT Pharma (EURONEXT ... About MaaT Pharma. MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival ... MAAT) since 2021.
Edit

Maat discoveries & Trumpaveli Movie Part 2

Bitchute 30 Mar 2025
Go to the source via the article link to view the video or click the video icon ....
Edit

MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 ...

Business Wire 27 Mar 2025
LYON, France--(BUSINESS WIRE)---- $MAAT #Cancer--Regulatory News. MaaT Pharma (EURONEXT. MAAT – the ...
Edit

MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results (Maat Pharma SA)

Public Technologies 27 Mar 2025
MaaT Pharma (EURONEXT ... Looking ahead, we look forward to bringing our innovation to patients in need and creating lasting value for all stakeholders,"stated Hervé Affagard, CEO and co-founder of MaaT Pharma ... About MaaT Pharma ... MAAT) since 2021.
×